Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I) (DCLI-I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01171703
Recruitment Status : Unknown
Verified July 2010 by Liu Chang-wei, gwcmc.
Recruitment status was:  Enrolling by invitation
First Posted : July 28, 2010
Last Update Posted : December 24, 2012
Beijing Tongren Hospital
Xuanwu Hospital, Beijing
Information provided by (Responsible Party):
Liu Chang-wei, gwcmc

Brief Summary:
The purpose of this trial is to find out the appropriate way to treat DM patients with critical limb ischemia. This trial includes two parts. Part I focuses on the treatment of femoral arterial lesion and part II focuses on the treatment of below-knee arterial lesion.

Condition or disease Intervention/treatment Phase
Vascular Diseases Diabetes Device: femoral-popliteal bypass Device: stent Phase 4

Detailed Description:
The trial includes two parts and here is part I. This part is a multi-center, prospective, randomized, controlled study to compare the therapeutic effect of stent and bypass to chronic long occlusion of the superficial femoral artery in DM patients. Totally 70 patients will be entered into the study. The lesion of the femoral artery should be TASC B、C or D and the patients should suffered ischemic symptom with Rutherford 3-6.The lesion does not extend beyond the aortoiliac artery or blow-knee popliteal artery, with at least 1 vessel infra-popliteal runoff to the foot.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I)
Study Start Date : November 2010
Estimated Primary Completion Date : July 2013
Estimated Study Completion Date : July 2016

Arm Intervention/treatment
Experimental: bypass
femoral-popliteal bypass
Device: femoral-popliteal bypass
Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.

Experimental: stent Device: stent
Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.

Primary Outcome Measures :
  1. Occlusion of the stent or bypass [ Time Frame: 36 months ]

Secondary Outcome Measures :
  1. Mortality [ Time Frame: 30 days ]
    The number of death during the first month after procedure, no matter whether the cause of death is related to the procedure.

  2. Rate of limb salvage [ Time Frame: 36 months ]
  3. Procedural complications, defined as any adverse event [ Time Frame: 36 months ]
    including MI, DVT, hematoma, renal failure, wound infection, lymphatic fistula

  4. Quality of Life assessment [ Time Frame: 36 months ]
    assessment in 1 month,6 months,12 months,24 months and 36 months post procedure

  5. Restenosis measured by Duplex Ultrasound or CTA [ Time Frame: 36 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patients volunteer to join the trial and sign the formal consent.
  • The patients are ≥55 year-old and ≤75 year-old.
  • The patients suffer from symptomatic leg ischemia with rutherford classification3, 4 , 5 or 6. The presentation is severe intermittent claudication, rest pain, ulcer or gangrene.
  • The lesion of the femoral artery should be TASC B、C or D.
  • The femoral-popliteal artery has never received bypass or endovascular therapy before.
  • No obvious stenosis or occlusion in the aortoiliac artery; or the lesion could be treated simultaneously or has already been cured.
  • No obvious stenosis in below-knee popliteal artery; at least 1 vessel infra-popliteal runoff to the foot.
  • No surgical contraindications;no infection in operation region.
  • Be diagnosed with DM for at least 1 year.

Exclusion Criteria:

  • Refuse random treatment.
  • Previous operations on the superficial femoral artery.
  • Acute lower extremity arterial thrombosis.
  • Serious major organ failure.
  • Allergic to the contrast agent or has contrast nephropathy.
  • No clinical compliance or unfit to join the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01171703

China, Beijing
Peking Union Medical College Hospital
Beijing, Beijing, China, 100032
Xuanwu Hospital, Beijing
Beijing, Beijing, China, 100053
Beijing Tongren Hospital
Beijing, Beijing, China, 100730
Sponsors and Collaborators
Beijing Tongren Hospital
Xuanwu Hospital, Beijing
Study Chair: Liu changwei, bachelor

Responsible Party: Liu Chang-wei, Vascular Surgery, gwcmc Identifier: NCT01171703     History of Changes
Other Study ID Numbers: pumch-DCLI-I
First Posted: July 28, 2010    Key Record Dates
Last Update Posted: December 24, 2012
Last Verified: July 2010

Keywords provided by Liu Chang-wei, gwcmc:
Critical limb ischemia
Femoropopliteal artery bypass

Additional relevant MeSH terms:
Vascular Diseases
Pathologic Processes
Cardiovascular Diseases